Milestone Pharmaceuticals Inc. is a private venture capital-funded cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. The company’s lead product, etripamil (MSP-2017), is entering Phase 3 development. Etripamil is a potent and short-acting nasally-delivered calcium channel antagonist in development for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT).
Milestone Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
Milestone Pharmaceuticals USA, Inc. today announced that Joseph G. Oliveto, President and Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27, 2018 at 9:50 a.m. Eastern Time.